Literature DB >> 19080995

[Recent results in relaps prevention of alcoholism with Disulfiram].

Jochen Mutschler1, Alexander Diehl, Christian Vollmert, Hans Herre, Karl Mann, Falk Kiefer.   

Abstract

OBJECTIVE: For more than 50 years, disulfiram has been approved for the treatment of chronic alcohol dependence. In the last years there has been observed an increase in the prescription of disulfiram in germany. It acts as a psychological deterrence of a possible disulfiram-alcohol reaction. This paper describes the current clinical impact and possible future of disulfiram.
METHODS: Clinical trials using disulfiram for the treatment of alcohol dependence were discussed. Furthermore, the options of combining disulfiram with novel anti-craving agents were considered. Moreover, experiences and results of a cross section of the Mannheimer Disulfiram program will be presented. RESULTS AND
CONCLUSIONS: Nowadays there exists consent in the matter that Disulfiram should only be adminsitered as part of a comprehensive therapy program, this means in the context of an intake under medical supervision. This paper is supposed to help estimate the value of disulfiram in recent addiction medicine.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19080995

Source DB:  PubMed          Journal:  Neuropsychiatr        ISSN: 0948-6259


  3 in total

1.  Proteasome inhibitor treatment reduced fatty acid, triacylglycerol and cholesterol synthesis.

Authors:  Joan Oliva; Samuel W French; Jun Li; Fawzia Bardag-Gorce
Journal:  Exp Mol Pathol       Date:  2012-03-16       Impact factor: 3.362

2.  [Disulfiram in outpatient treatment of alcohol dependency].

Authors:  K Hochsattel; P Brieger
Journal:  Nervenarzt       Date:  2016-05       Impact factor: 1.214

3.  Long-term γ-hydroxybutyric acid (GHB) and disulfiram combination therapy in GHB treatment-resistant chronic alcoholics.

Authors:  Angelo Giovanni Icro Maremmani; Pier Paolo Pani; Luca Rovai; Matteo Pacini; Liliana Dell'Osso; Icro Maremmani
Journal:  Int J Environ Res Public Health       Date:  2011-07-06       Impact factor: 3.390

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.